Press Releases

November 13, 2023

Replicor updates REP 2139-Mg compassionate use and mechanistic data at AASLD 2023

October 2, 2023

Replicor announces activity of REP 2139 in HBV / HDV / HIV co-infection in its first Canadian patient

September 25, 2023

Replicor announces the description of direct acting activity of REP 2139 against HDV

July 24, 2023

Replicor announces rapid HBsAg loss with NAPs predicts HBV functional cure

June 28, 2023

Replicor updates REP 2139-Mg compassionate use clinical data at EASL 2023

May 10, 2023

Latest Replicor clinical data on NAPs highlighted at DDW 2023

May 1, 2023

Replicor updates clinical data on NAPs in three oral presentations at the 2023 Global Hepatitis Summit

February 21, 2023

Replicor expands treatment success against HBV and HDV infection with REP 2139-Mg

October 12, 2022

Replicor discloses anti-inflammatory properties of REP 2139

September 21, 2022

Replicor expands efficacy and safety envelope in decompensated cirrhosis with compassionate use of subcutaneous REP 2139-Mg

June 1, 2022

Replicor expands compassionate use of REP 2139-Mg in bulvertide failure patients

May 4, 2022

Replicor updates concepts in understanding approaches to functional cure of HBV

April 4, 2022

Replicor successfully confirms NAPs target Hepatitis B subviral particles

March 29, 2022

Replicor announces post-mortem analysis of ALG-10133 failure

November 2, 2021

Replicor announces transition of REP 2139-Mg to subcutaneous administration at AASLD 2021

September 30, 2021

Replicor publishes experimental marker analysis from its REP 401 study indicating inactivation of cccDNA and elimination of integrated HBV DNA

April 26, 2021

Replicor announces the publication of a review on the safety and importance of transaminase flares in achieving functional cure of HBV infection

February 15, 2021

Replicor demonstrates therapeutic benefit of liver enzyme flares during therapy in achieving functional cure of HBV

December 14, 2020

Replicor announces the publication of an updated review on the critical role of targeting subviral particles to achieve functional cure of HBV infection

November 18, 2020

Replicor publishes its REP 301-LTF study achieving durable functional cure of HDV and HBV, inactivation of cccDNA and elimination of integrated HBV DNA

November 2, 2020

Replicor announces four presentations at AASLD including NAP target identification and well tolerated efficacy in cirrhotic infection

September 10, 2020

Replicor announces presentation of experimental endpoint data at EASL

July 24, 2020

Replicor publishes follow-on study expanding its mechanistic understanding of REP 2139

July 13, 2020

CSO Dr. Andrew Vaillant to present overview of critical role of HBsAg in functional cure

May 12, 2020

Replicor announces publication of modelling study demonstrating potent activity of NAPs against HBV and HDV infection

March 9, 2020

Replicor announces publication of the REP 401 study achieving high rates of virologic control and functional cure in patients with chronic hepatitis B infection

December 5, 2019

Replicor to present updated clinical data at HEPDART 2019

July 29, 2019

Replicor announces publication of new study examining HBsAg evolution during REP 2139

June 10, 2019

Replicor presents final REP 401 data demonstrating persistent functional cure of HBV

April 1, 2019

Replicor to present latest data on the beneficial impact of transaminase flares in achieving HBV functional cure at the 2019 EASL ILC meeting

March 1, 2019

Replicor to present data on beneficial effects of transaminase flares on HBV functional cure at 2019 EASL AASLD Endpoints Meeting

February 18, 2019

Replicor announces publication of new study examining antiviral mechanisms of REP 2139

February 11, 2019

Replicor to update analysis of high rates of functional cure of HBV at APASL 2019

November 21, 2018

Replicor announces publication of new study validating HBsAg responses driven by REP 2139

November 6, 2018

Replicor to disclose achievement of high rates of functional cure of HBV at AASLD 2018

October 15, 2018

Replicor showcases HBV functional cure data with REP 2139-Mg

September 17, 2018

Replicor publishes updated review of REP 2139 and its application in treating HBV and HDV

June 18, 2018

Replicor demonstrates high rates of persistent functional control of HBV infection following cessation of all therapy

June 11, 2018

Replicor updates mechanistic and clinical data demonstrating high rates of functional control of HBV and HDV infection at The Science of HBV Cure 2018

April 13, 2018

Replicor discloses long term functional control of HBV and HDV infection in high proportions of treated patients at EASL 2018

April 3, 2018

Replicor to disclose updated data demonstrating functional remission of HBV and HDV at the EASL International Liver Conference 2018

December 20, 2017

Replicor announces publication of its latest pre-clinical hepatitis B study:

December 12, 2017

Replicor announces publication of its in vitro study on NAP activity in HDV

November 28, 2017

Replicor to disclose clinical update on the REP 401 trial at HEP DART 2017

November 9, 2017

Replicor announces publication of its study on NAP activity in rodent models of HBV infection

November 6, 2017

Replicor and the INRS – Institut Armand-Frappier collaborate to identify the mechanisms of subviral particle assembly

October 23, 2017

Replicor discloses the persistence of functional control off-therapy in 80% of patients with chronic hepatitis B from the REP 401 study at AASLD 2017

October 10, 2017

Replicor to disclose late-breaking follow-up data from its REP 401 study at AASLD 2017

October 2, 2017

Replicor showcases updated technology summary of NAPs at the Inaugural Targeting HBV Symposium

September 28, 2017

Replicor announces publication of its REP 301 study in HBV / HDV co-infection in The Lancet Gastroenterology & Hepatology

September 12, 2017

Replicor updates NAP development with seven presentations at the 2017 International HBV Meeting

August 28, 2017

Six Replicor presentations to be featured at the 2017 International HBV Meeting

June 28, 2017

Replicor announces publication of its studies on the antiviral activity of NAPs in recognized in vitro models of HBV infection

June 12, 2017

Replicor announces publication of pre-clinical safety and pharmacokinetic data on NAPs

April 20, 2017

Replicor discloses achievement of 1 year functional control of HBV and HDV with NAPs and new mechanistic insights in NAP pharmacology

April 3, 2017

Replicor to Make Five Presentations at EASL 2017

March 23, 2017

Replicor announces publication of study showing NAPs do not directly stimulate the immune response

February 20, 2017

Replicor discloses high rates of HBsAg loss with NAP combination therapy at APASL 2017

February 10, 2017

Replicor discloses updated REP 401 clinical data at APASL 2017

November 15, 2016

Replicor discloses late breaking HBV and follow-up HBV / HDV clinical data at AASLD 2016

October 14, 2016

Replicor to present keynote presentation at the 3rd World Conference of Hepatitis and Liver Diseases, Dubai, UAE

October 7, 2016

Replicor to present keynote presentation at the 3rd World Conference of Hepatitis and Liver Diseases, Dubai, UAE

October 4, 2016

Replicor to disclose late breaking HBV clinical data at AASLD 2016

September 21, 2016

Replicor to present new HBV and HDV mechanistic data for its NAP technology

August 2, 2016

Replicor announces publication of its REP 101 and REP 102 studies demonstrating the therapeutic effect of NAPs and the achievement of functional control off treatment in human patients with chronic hepatitis B infection.

June 7, 2016

Replicor announces publication of its REP 101 and REP 102 studies demonstrating the therapeutic effect of NAPs and the achievement of functional control off treatment in human patients with chronic hepatitis B infection.

April 4, 2016

Replicor to Make Three Presentations at EASL 2016

February 16, 2016

Replicor to present pre-clinical and updated clinical data on REP 2139-Ca based combination therapy in chronic HBV and HBV / HDV co-infection at APASL 2016

December 1, 2015

Replicor to present pre-clinical and clinical data on REP 2139-Ca based combination therapy in chronic HBV / HDV co-infection at HEPDART 2015

November 16, 2015

Replicor discloses continued improvement of the antiviral response in patients with HBV / HDV co-infection receiving REP 2139-Ca based combination therapy

November 11, 2015

Replicor announces publication of its pre-clinical data on the therapeutic effect of NAPs on hepatitis B virus infection.

November 9, 2015

Replicor announces grant of US patents on HBV / HDV treatment methods combining HBsAg reduction and immunotherapy

November 3, 2015

Replicor to present an update on the safety and efficacy of REP 2139-Ca based combination therapy in chronic HBV / HDV co-infection at AASLD 2015

October 15, 2015

Replicor presents updated mechanistic data and pre-clinical interferon-free combination treatment data in HBV and HBV / HDV co-infection

October 5, 2015

Replicor announces initiation of recruitment for its Phase IIb clinical trial with REP 2139-Mg or REP 2165-Mg in combination with Viread® and Pegasys® or Zadaxin® in patients with HBeAg negative chronic hepatitis B infection

September 9, 2015

Replicor to participate at the 6th DIA / FDA Oligonucleotide-Based Therapeutics Conference

July 29, 2015

Replicor to participate in the Jefferies Hepatitis B Summit in Boston

June 30, 2015

Replicor discloses updated clinical trial data to the Global Virus Hepatitis Summit in Berlin

June 10, 2015

Replicor to Present at the Israel Association for the Study of Liver Conference and the Global Virus Hepatitis Summit in Berlin in June

April 29, 2015

Significant reduction of HBsAg and HDV RNA by REP 2139-Ca in Caucasian patients with HBV / HDV co-infection

April 27, 2015

Replicor Announces Four Appointments to Scientific Advisory Board Doug Kornbrust, Ph.D., D.A.B.T.; Jennifer Lockridge, Ph.D.; Michael Roggendorf, M.D.; and Christian Trepo, M.D., Ph.D.

April 10, 2015

Replicor to Present at the 2015 Lancet Viral Hepatitis Conference

April 8, 2015

Replicor to Make Six Presentations at EASL 2015

April 2, 2015

Replicor Announces Completion of Enrollment in Phase II Trial

December 1, 2014

Replicor a biopharmaceutical company targeting a cure for Chronic Hepatitis B patients will present updated human clinical trial data documenting a 4 to 6 log reduction in s-antigen and a long-term SVR in 80% of patients.

October 7, 2014

Replicor to present updated clinical trial data with combination treatment using its HBsAg-release inhibitors in patients with chronic hepatitis B infection at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society.

October 1, 2014

Replicor announces initiation of its Phase II clinical trial with REP 2139-Ca in combination with Pegasys™ in patients with hepatitis B / hepatitis D co-infection

November 3, 2013

Replicor publishes the initial pre-clinical development of its NAP technology, including REP 2055, for the treatment of chronic HBV infection.

May 14, 2013

Replicor presents clinical efficacy and toxicology results in patients with chronic hepatitis B with short term exposure to immunotherapy after REP 2139-ca induced clearance of serum HBsAg.

April 26, 2013

Replicor presents updated clinical efficacy results in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139-ca and new clinical data in patients receiving this combination treatment while currently on entecavir (triple combination therapy).

February 27, 2013

Replicor updates clinical efficacy results in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139

November 12, 2012

Replicor updates clinical results demonstrating the achievement of therapeutic vaccine-like responses in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139

September 25, 2012

Replicor discloses achievement of therapeutic vaccine-like responses in patients with chronic hepatitis B with short term exposure to immunotherapy in combination with REP 2139

June 22, 2012

Replicor to disclose interim REP 2055 / 2139 clinical efficacy data in patients with chronic hepatitis B at the 14th International Symposium of Viral Hepatitis and Liver Disease (ISVHLD 2012)

February 17, 2012

Replicor to disclose interim REP 2139 clinical efficacy data in patients with chronic hepatitis B at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012).

November 25, 2011

Replicor to disclose new mechanism of action data and interim REP 2055 and REP 2139 clinical efficacy data in patients with chronic hepatitis B at the 2011 HEPDART meeting.

October 27, 2011

Replicor to disclose interim REP 2055 clinical efficacy data in patients with chronic hepatitis B at the 62nd annual meeting of the American Association for the Study of Liver Diseases (AASLD 2011)

March 30, 2011

Replicor to disclose interim REP 2055 clinical efficacy data in patients with chronic hepatitis B at the 46th meeting of the European Association for the Study of the Liver (EASL 2011)

February 17, 2011

Replicor to disclose interim REP 2055 clinical efficacy data in patients with chronic hepatitis B at the 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011)

October 28, 2010

Replicor to disclose interim REP 2055 clinical efficacy data in patients with chronic hepatitis B at the 61st annual meeting of the AASLD in Boston, U.S.A.

March 18, 2010

Replicor to present interim REP 2055 clinical efficacy data at the 20th annual meeting of the APASL in Beijing, China

December 8, 2009

Dr. Allison Jilbert presents preclinical efficacy data for REP 2055 in DHBV infected Pekin ducks

December 2, 2009

Replicor publishes data on the activity and safety of amphipathic DNA polymers (APs) in cytomegalovirus infection

April 23, 2009

Publication of Replicor’s first in class HCV entry inhibitor based on its amphipathic DNA polymer technology

April 16, 2009

Replicor publishes data on mechanism of action and pre-clinical efficacy of amphipathic DNA polymers (APs) in HCV infection

March 31, 2009

Replicor to present preclinical data showing a curative response to hepatitis B infection with its drug at the 1st Annual Girindus Leaders in Oligonucletides Meeting

March 1, 2009

Replicor initiates dosing of human patients with its drug

February 1, 2009

Replicor receives IRB approval to conduct a phase I / II trial to test the safety and efficacy of its drug in patients with chronic hepatitis B and hepatitis C.